What internists should know about amiodarone

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 3, 1998, Pages 159-166

  Murphy, Mark T ^a,b   Wilkoff, Bruce L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROYAL COLLEGE OF PHYSICIANS OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CHOLESTEROL; CORTICOSTEROID; DIGOXIN; PLACEBO; PROCAINAMIDE; QUINIDINE; WARFARIN;

ANTIARRHYTHMIC ACTIVITY; CARDIOTOXICITY; CARDIOVERSION; CLINICAL TRIAL; CORNEA DISEASE; DEFIBRILLATION; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; INTERNAL MEDICINE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MEDICAL SPECIALIST; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SKIN TOXICITY; SUDDEN DEATH; THYROID DISEASE;

EID: 2642670288     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.3.159     Document Type: Review

References (30)

1. Meyer JB, Amann FW. Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. Am Heart J 1993; 125:996-1001.
2. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. Ann Intern Med 1994; 121:529-535.
3. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995; 122:689-700.
4. Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993; 72:45F-50F.
5. Mason JW. Amiodarone. N Engl J Med 1987; 316:455-466.
6. Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983; 106:840-847.
7. Tielman RG, Gosselink ATM, Crijns H JGM, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79:53-57.
8. Middlekauf HR, Wiener I, Stevenson WG. Low dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72:75F-81F.
9. Daoud EG, Strickberger SA, Ching Man K, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337:1785-1791.
10. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309:331-336.
11. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
12. The Cardiac Arrhythmia Suppression Trial 2 Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
13. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16:1711-1718.
14. Cairns JA, Connolly SJ, Roberts R, Gent M, for the CAMIAT investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349:675-682.
15. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674.
16. Doval HC, Nul DR, Granecelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344:493-498.
17. Singh SN, Fletcher RD, Fisher S, et al, for the CHF STAT investigators. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrythmia. N Engl J Med 1995; 333:77-82.
18. Hammill SC, Packer DL. Amiodarone in congestive heart failure: unravelling the GESICA and CHF STAT differences (editorial). Heart 1996; 75:6-7.
19. Moss AJ, Hall WJ, Cannom DS, et al, for the MADIT investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335:1933-1940.
20. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13:442-449.
21. The CASCADE investigators. Randomised antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993; 72:70F-74F.
22. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal arrhythmias. N Engl J Med 1997; 337:1576-1583.
23. Martin WJ 2d, Rosenow EC 3d. Amiodarone pulmonary toxicity.Recognition and pathogenesis.Chest 1988; 93:1067-64.
24. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51-59.
25. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 121:158-171.
26. Harjai KT, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126:63-73.
27. Wiersinga WM, Trip MD, van Beeren MH, Plomp TA, Oosting H. An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. Ann Intern Med 1991; 114:128-132.
28. Marcus FI. Drug interactions with amiodarone. Am Heart J 1983; 106:924-930.
29. Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996; 78 (suppl 4A):41-53.
30. Evans SJL, Myers M, Zaher C, et al. High-dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. J Am Coll Cardiol 1992; 19:169-173.